Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Papillary | 3 | 2019 | 96 | 0.680 |
Why?
|
| Breast Neoplasms | 6 | 2019 | 2751 | 0.530 |
Why?
|
| Radiology Department, Hospital | 1 | 2017 | 25 | 0.520 |
Why?
|
| Spinal Cord Compression | 1 | 2017 | 34 | 0.520 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2019 | 93 | 0.510 |
Why?
|
| Spinal Neoplasms | 1 | 2017 | 76 | 0.500 |
Why?
|
| Ambulatory Care Facilities | 1 | 2017 | 242 | 0.450 |
Why?
|
| Receptors, Estrogen | 3 | 2013 | 829 | 0.440 |
Why?
|
| Mucin-4 | 1 | 2012 | 11 | 0.390 |
Why?
|
| Receptor, ErbB-2 | 2 | 2019 | 562 | 0.320 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2012 | 829 | 0.270 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 1351 | 0.230 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2021 | 32 | 0.180 |
Why?
|
| Mouth | 1 | 2021 | 72 | 0.170 |
Why?
|
| Veterans Health | 1 | 2021 | 180 | 0.160 |
Why?
|
| Carbon Isotopes | 1 | 2019 | 274 | 0.150 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 260 | 0.150 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2021 | 284 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2019 | 169 | 0.140 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 1363 | 0.130 |
Why?
|
| Survival Analysis | 2 | 2019 | 1584 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 1 | 2022 | 635 | 0.130 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 5436 | 0.120 |
Why?
|
| Cell-Matrix Junctions | 1 | 2015 | 10 | 0.120 |
Why?
|
| Twist-Related Protein 1 | 1 | 2015 | 39 | 0.120 |
Why?
|
| Glucose | 1 | 2019 | 916 | 0.110 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2015 | 74 | 0.110 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 75 | 0.110 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 242 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 249 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2017 | 415 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 739 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 252 | 0.100 |
Why?
|
| Middle Aged | 7 | 2021 | 28950 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 1558 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 1013 | 0.090 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 306 | 0.090 |
Why?
|
| SEER Program | 1 | 2013 | 222 | 0.090 |
Why?
|
| Estrogen Antagonists | 1 | 2012 | 107 | 0.090 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 449 | 0.090 |
Why?
|
| Trastuzumab | 1 | 2012 | 154 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2012 | 256 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2022 | 3863 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 446 | 0.090 |
Why?
|
| Quinazolines | 1 | 2012 | 185 | 0.090 |
Why?
|
| Female | 10 | 2022 | 71436 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2015 | 3794 | 0.090 |
Why?
|
| Gene Expression | 2 | 2012 | 1608 | 0.080 |
Why?
|
| Tamoxifen | 1 | 2012 | 375 | 0.080 |
Why?
|
| Mice, Nude | 1 | 2012 | 780 | 0.080 |
Why?
|
| Prognosis | 3 | 2019 | 5042 | 0.080 |
Why?
|
| Veterans | 1 | 2021 | 1782 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2015 | 1072 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 407 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2012 | 910 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 1013 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 1067 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 1341 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2022 | 17555 | 0.070 |
Why?
|
| Survival Rate | 1 | 2013 | 2208 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 555 | 0.070 |
Why?
|
| Humans | 11 | 2022 | 133257 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 674 | 0.060 |
Why?
|
| Nasal Septum | 1 | 2006 | 20 | 0.060 |
Why?
|
| Cartilage, Articular | 1 | 2006 | 64 | 0.060 |
Why?
|
| Transcriptome | 1 | 2012 | 1135 | 0.060 |
Why?
|
| Incidence | 1 | 2013 | 3389 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2021 | 13103 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 1136 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1692 | 0.060 |
Why?
|
| Texas | 1 | 2013 | 3664 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 1471 | 0.050 |
Why?
|
| Phenotype | 1 | 2012 | 4577 | 0.050 |
Why?
|
| Cystoscopy | 1 | 2022 | 46 | 0.050 |
Why?
|
| Glossectomy | 1 | 2021 | 10 | 0.050 |
Why?
|
| Laryngectomy | 1 | 2021 | 34 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 965 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2021 | 168 | 0.040 |
Why?
|
| Free Tissue Flaps | 1 | 2021 | 59 | 0.040 |
Why?
|
| Collagen | 2 | 2015 | 314 | 0.040 |
Why?
|
| Radiography | 1 | 2022 | 821 | 0.040 |
Why?
|
| Mice | 2 | 2019 | 18937 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2012 | 4917 | 0.040 |
Why?
|
| Risk | 1 | 2021 | 782 | 0.040 |
Why?
|
| Animals | 3 | 2019 | 36203 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 1307 | 0.030 |
Why?
|
| Aged | 4 | 2021 | 21475 | 0.030 |
Why?
|
| Male | 3 | 2021 | 65522 | 0.030 |
Why?
|
| Elasticity | 1 | 2015 | 93 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 7138 | 0.030 |
Why?
|
| Algorithms | 1 | 2022 | 1730 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2015 | 130 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 1240 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1340 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2015 | 614 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 546 | 0.030 |
Why?
|
| Transfection | 1 | 2015 | 1095 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2015 | 505 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 1582 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 625 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 6545 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 622 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 699 | 0.020 |
Why?
|
| Adult | 3 | 2019 | 31646 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1463 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 4759 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 1863 | 0.020 |
Why?
|
| Endopeptidase K | 1 | 2006 | 4 | 0.020 |
Why?
|
| Compressive Strength | 1 | 2006 | 14 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 2006 | 34 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2006 | 75 | 0.020 |
Why?
|
| Anisotropy | 1 | 2006 | 126 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2006 | 161 | 0.020 |
Why?
|
| Temperature | 1 | 2006 | 325 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 9923 | 0.010 |
Why?
|
| Tissue Engineering | 1 | 2006 | 180 | 0.010 |
Why?
|
| Adolescent | 1 | 2006 | 20549 | 0.000 |
Why?
|